[HTML][HTML] Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular cancer, 2018 - Springer
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular Cancer, 2018 - go.gale.com
Background In the United States, an additional 224,390 new lung cancer cases were
diagnosed in 2016, and accounted for about 27% of all cancer deaths [1]. Although standard …
diagnosed in 2016, and accounted for about 27% of all cancer deaths [1]. Although standard …
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular cancer, 2018 - pubmed.ncbi.nlm.nih.gov
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.
SG Wu, JY Shih - Molecular Cancer, 2018 - europepmc.org
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
[HTML][HTML] Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular Cancer, 2018 - molecular-cancer.biomedcentral …
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer.
SG Wu, JY Shih - Molecular Cancer, 2018 - search.ebscohost.com
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
[引用][C] Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular Cancer, 2018 - cir.nii.ac.jp
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell
lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
[HTML][HTML] Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular Cancer, 2018 - ncbi.nlm.nih.gov
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.
SG Wu, JY Shih - Molecular Cancer, 2018 - europepmc.org
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
[PDF][PDF] Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - 2018 - molecular-cancer.biomedcentral …
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …